IL6 and atherosclerosis: In the mechanistic study of the drug, modified Zhujing formula [31], Elephantopus scaber Linn [32] decreased the expression of IL-6 by inhibiting TLR4 and downregulating NF-κB. In atherosclerosis (AS) clinical drug trials, SQMXTJN blocked TLR4/NF-κB signaling pathway and downregulated the expression of TLR4, NF-κB, IL-6, TNF-α, and other proteins in the serum of AS patients, thereby reducing inflammation, acting as an antiatherosclerotic agent and slowing down the progression of AS [33].